Tag: collaborations

Strategic supply and license agreement will accelerate access for North and South American corn and soybean growersPHILADELPHIA and INDIANAPOLIS, June 16, 2026 /PRNewswire/ --...

Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize...

BENGALURU, India, June 16, 2026 /PRNewswire/ -- Marking a significant milestone in the evolution of Child Life services in India, Manipal Hospital Yelahanka, in collaboration...

Launching a resort-wide "Wing Lei Bar & Friends" Special Edition, Wynn will unite over 50 global mixology and culinary visionaries from July 24 to 29MACAO,...

HONG KONG, June 16, 2026 /PRNewswire/ -- XTransfer, the world's leading B2B cross-border trade payment platform, is proud to announce that it has been...

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

New collaboration provides framework between the Japan government and ItalyTOKYO, June 15, 2026 /PRNewswire/ -- Rapidus Corporation today announced that it signed a Memorandum of...

WINSTON-SALEM, N.C., June 15, 2026 /PRNewswire/ -- The color powder may fade, but the PACU Foundation's impact won't. ...

SHERIDAN, Wyo., June 15, 2026 /PRNewswire/ -- The global laboratory filtration market is projected to grow from USD 4.5 billion in 2025 to USD...

TAIPEI, June 15, 2026 /PRNewswire/ -- Ganzin Technology, a leader in ultra-low-power wearable eye-tracking solutions, announced major ecosystem advancements at AWE 2026, highlighting collaborations...

New collaboration provides framework between the Japan government and the UKTOKYO, June 14, 2026 /PRNewswire/ -- Rapidus Corporation today announced that it signed a...

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery...

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.